EFFECTS OF POSITIVE AIRWAY PRESSURE THERAPY ON NEUROBEHAVIORAL OUTCOMES IN CHILDREN WITH OBSTRUCTIVE SLEEP APNEA

<table>
<thead>
<tr>
<th>Journal:</th>
<th>American Journal of Respiratory and Critical Care Medicine</th>
</tr>
</thead>
<tbody>
<tr>
<td>Manuscript ID:</td>
<td>Blue-201112-2167OC.R1</td>
</tr>
<tr>
<td>Manuscript Type:</td>
<td>OC - Original Contribution</td>
</tr>
<tr>
<td>Date Submitted by the Author:</td>
<td>26-Jan-2012</td>
</tr>
<tr>
<td>Complete List of Authors:</td>
<td>Marcus, Carole; Children's Hospital of Philadelphia, Pulmonary Radcliffe, Jerilynn; Children's Hospital of Philadelphia, Child Development Konstantinopoulou, Sofia; Children's Hospital of Philadelphia, Pulmonary Medicine Beck, Suzanne; Children's Hospital of Philadelphia, Pulmonary Medicine Cornaglia, Mary Anne; Children's Hospital of Philadelphia, Research Traylor, Joel; Children's Hospital of Philadelphia, Nursing - Respiratory and Diag. DiFeo, Natalie; Children's Hospital of Philadelphia, Nursing Karamessinis, Laurie; Connecticut Children's Medical Center, Gallagher, Paul; The Children's Hospital of Philadelphia, Research Meltzer, Lisa; National Jewish Health,</td>
</tr>
<tr>
<td>Keywords:</td>
<td>CPAP, obstructive sleep apnea, sleepiness</td>
</tr>
</tbody>
</table>
EFFECTS OF POSITIVE AIRWAY PRESSURE THERAPY ON 
NEUROBEHAVIORAL OUTCOMES IN CHILDREN WITH OBSTRUCTIVE 
SLEEP APNEA

Carole L. Marcus, MBBCh¹, Jerilynn Radcliffe, PhD², Sofia Konstantinopoulou, MD¹,
Suzanne E. Beck, MD¹, Mary Anne Cornaglia¹, Joel Traylor, RPsgT¹, Natalie DiFeo,
CRNP¹, Laurie R. Karamessinis, RPFT¹, Paul R. Gallagher, MA², Lisa J. Meltzer, PhD³

Sleep Center ¹ and Clinical and Translational Research Center ², Children’s Hospital of
Philadelphia, University of Pennsylvania School of Medicine, Philadelphia, PA; and
Division of Pediatric Behavior Health, Denver National Health, Denver, CO³

Address for Correspondence:
Carole L. Marcus, M.B.B.Ch.
Children's Hospital of Philadelphia
Main Building, 9NW50
34th Street & Civic Center Boulevard
Philadelphia, PA 19104
Phone: 267-426-5842
Fax: 267-426-9234
E-mail: marcus@email.chop.edu

Running head: Neurobehavioral effects of PAP in children
Financial support: This was an investigator-initiated (CLM) study funded by Philips Respironics. All data collection, statistical analyses and manuscript writing were performed by the investigators independent of Philips Respironics. Dr. Marcus also received support from NIH HL58585, and Dr. Meltzer from K23 MH077662.

Role of authors: Dr. Marcus was the Principal Investigator and was responsible for all aspects of study design, data collection, data analysis and manuscript preparation. Drs. Meltzer and Radcliffe helped with the selection and interpretation of the social and psychometric survey instruments and were involved in study design, data analysis and manuscript preparation. Dr. Konstantinopoulou assisted with data analyses and manuscript preparation. Dr. Beck was the unblinded physician safety monitor. Ms. Karamessinis and Cornaglia were study coordinators and participated in subject recruitment, data collection and data entry. Mr. Traylor managed the database and adherence data collection and analysis. Ms. Difeo was study nurse and provided subject evaluation and support, fitted equipment, evaluated and managed side-effects in conjunction with study physicians and provided behavioral counseling for CPAP use. Mr. Gallagher was responsible for statistical analyses and was involved in study design and manuscript preparation.

This manuscript has been published in abstract form: Difeo NE et al. Effects of Positive Airway Pressure (PAP) On Neurobehavioral Function In Children. Sleep 2009; 32S:A0259.
At a Glance Commentary:

Scientific Knowledge on the Subject: The childhood obstructive sleep apnea syndrome is common, and some of these children require positive airway pressure therapy. Although neurobehavioral disturbances are important comorbidities of childhood sleep apnea, the efficacy of positive airway pressure therapy in treating these neurobehavioral deficits is unknown.

What This Study Adds to the Field: This study confirms that neurobehavioral deficits such as daytime sleepiness, deficits in attention, behavioral problems and decreased quality of life, are common in children with obstructive sleep apnea. This study is the first to show highly significant improvements in multiple neurobehavioral domains in response to positive airway pressure therapy in children.

This article has an online data supplement, which is accessible from this issue's table of content online at www.atsjournals.org

Descriptor number: 14.5 Pediatric Sleep and Control of Breathing

Total word count: 2,370
ABSTRACT

**Rationale:** Positive airway pressure therapy is frequently used to treat obstructive sleep apnea in children. However, it is not known whether positive airway pressure therapy results in improvements in the neurobehavioral abnormalities associated with childhood sleep apnea.

**Objectives:** We hypothesized that positive airway pressure therapy would be associated with improvements in attention, sleepiness, behavior, and quality of life, and that changes would be associated with therapy adherence.

**Methods:** Neurobehavioral assessments were performed at baseline and after 3 months of positive airway pressure therapy in a heterogeneous group of 52 children and adolescents.

**Measurements and Main Results:** Adherence varied widely (mean use 170±145 [SD] minutes/night). Positive airway pressure therapy was associated with significant improvements in attention deficits (p<0.001), sleepiness on the Epworth scale (p<0.001), behavior (p<0.001), and caregiver- (p=0.005) and child- (p<0.001) reported quality of life. There was a significant correlation between the decrease in Epworth Sleepiness Scale at 3 months and adherence (r=0.411, p=0.006), but not between other behavioral outcomes and adherence. Behavioral factors also improved in the subset of children with developmental delays.

**Conclusions:** These results indicate that, despite suboptimal adherence use, there was significant improvement in neurobehavioral function in children after three months of positive airway pressure therapy, even in developmentally delayed children. The
implications for improved family, social, and school function are substantial.

**Word count:** 216

**Key words:** CPAP, obstructive sleep apnea, sleepiness
INTRODUCTION

The obstructive sleep apnea syndrome (OSAS) affects up to 4% of children\(^1\). In most children, OSAS is associated with adenotonsillar hypertrophy, and improves after adenotonsillectomy\(^2\). However, a significant proportion of children have residual OSAS post-operatively\(^3\). Furthermore, many children with OSAS have other underlying conditions such as obesity or Down syndrome. In these children, continuous positive airway pressure (CPAP) is usually used as the second line of treatment\(^2\). Although CPAP is now being used commonly in children, only a handful of studies have evaluated its efficacy.

If left untreated, OSAS may lead to substantial comorbidities. In particular, childhood OSAS has been shown to be associated with behavioral disturbances and learning deficits\(^4\). The effect of positive airway pressure (PAP) therapy in treating these neurobehavioral deficits in children is unknown. We therefore prospectively evaluated changes in neurobehavioral parameters, including symptoms of attention-deficit/hyperactivity disorder (ADHD), sleepiness, behavior, and quality of life, at baseline and following 3 months of PAP, in children with OSAS. We hypothesized that children treated effectively with PAP, including children with developmental delays, would show improvements in neurobehavioral outcomes.

Some of the results of these studies have been previously reported in the form of an abstract\(^5\).
METHODS

See the online supplement for additional details.

This study was conducted prospectively as part of a clinical trial comparing two modes of PAP delivery: CPAP vs bilevel pressure release (Bi-Flex); no difference in adherence or efficacy was found between the modes. Children with OSAS aged 2-16 years, who were naïve to PAP and clinically required PAP, were eligible. The study was approved by the Institutional Review Board of The Children’s Hospital of Philadelphia. Written informed consent was obtained from the parent/legal guardian, and assent from children 7 years of age or older when able.

All subjects underwent baseline clinical polysomnography prior to study entry. Subjects then had a 2-week habituation period at home, followed by a PAP titration study. At the end of 3 months, polysomnography was repeated on PAP, and objective adherence data were downloaded (EncorePro2, Philips Respironics, Murrysville, PA).

Neurobehavioral surveys were administered at baseline and after 3 months of PAP use. Based on known data regarding the domains affected by childhood OSAS, the following were evaluated:

1. **Sleepiness**, using the *Epworth Sleepiness Scale* modified for children. A score > 12 was considered abnormal as it was >95th percentile for normal children.

2. **Behavioral problems**, using the *Child Behavior Checklist* (CBCL). This is a survey of behavior competencies that yields standardized, age-adjusted scores on
internalizing, externalizing and total behavior difficulties. Scores between 60-63 are borderline; scores > 63 are abnormal.

3. **ADHD**, using both the *Conners Abbreviated Symptom Questionnaire* and the *Attention Problems* subscale of the CBCL. The Conners scale evaluates inattention, distractibility, and overactivity. Scores range from 0-30; > 15 is considered clinically relevant\(^\text{12}\).

4. **Quality of life** was measured using two instruments. The *Pediatric Quality of Life Inventory* (PedsQL)\(^\text{13}\) is a well-validated measure of global quality of life. The score ranges from 0-100; the cutoff for moderate to severe impairment in quality of life is >73 for children <8 years, and >65 for children >8 years\(^\text{14}\). The *OSAS-I8\(^\text{15}\)* is a composite of OSAS-related symptoms and disease-specific quality of life. Scores range from 18-126. Scores <60 suggest a small impact, 60-80 suggest a moderate impact and >80 suggest a large impact of OSAS on quality of life.

Surveys were completed by the same caregiver at each time point. In addition, developmentally able youths aged 11-18 completed the CBCL Youth Self Report, and those ≥5 years completed the PedsQL.

**Statistical Analysis**

Unless otherwise specified, data are shown as mean ± SD. Differences between subjects at baseline vs 3 months were analyzed using paired Student’s t-tests, Wilcoxon signed rank tests or McNemar tests of equality of paired proportions. Differences between those who dropped out vs those who completed the study were evaluated using unpaired Student’s t-tests, Mann Whitney rank sum tests or Fisher exact test. Pearson or Spearman
correlations were used to determine the relationship between adherence and behavioral outcomes. Analysis of covariance models were used evaluate the effects of demographic variables on neurobehavioral outcomes. p<0.05 was considered significant.

RESULTS

Study Group
Details of enrollment have been published elsewhere. 60 subjects were initially enrolled; 4 were excluded due to medical interventions preventing PAP use, institutionalization or moving. Four subjects were lost to follow-up. One subject followed-up with neurocognitive testing but declined repeat polysomnography; this subject was included for analyses other than polysomnography. Thus, 52 subjects completed the study. There were no differences in baseline parameters between those lost to follow-up vs those who completed the study.

Details of the study group are shown in Table 1. As is typical for childhood OSAS, where CPAP is usually reserved for children who fail surgical therapy, the study group was heterogeneous, with many children having underlying medical conditions such as obesity or genetic syndromes. Of note, 19% of subjects had developmental delays (Table 1). Overall, subjects had severe OSAS by pediatric standards (Table 2).

Efficacy and Adherence
All subjects had adequate control of their OSAS by PAP on the titration night, with highly significant improvements in respiratory and sleep parameters compared to baseline
(Table 2). There was a large variability in adherence, although most subjects attempted to use PAP on most nights (Table 1).

**Neurobehavioral Changes**

A large number of subjects had neurobehavioral scores in the clinically abnormal range (Table 3). After three months of PAP use, there were highly significant improvements in almost all domains (Figures 1-3). There were significant improvements in symptoms of ADHD (p<0.001 for the Conner’s scale and p=0.005 for the Attention Problems subscale of the CBCL) and daytime sleepiness on the Epworth scale (p<0.001). By parental report, internalizing behavior symptoms and total behavior, as measured by the Child Behavior Checklist (CBCL), improved (both p<0.001), although externalizing behavior symptoms did not (p=0.181). Twenty three subjects who were old enough and developmentally able completed the CBCL youth self report. For the youth CBCL self report, all 3 domains improved significantly (p=0.023 for internalizing symptoms, p<0.001 for externalizing symptoms and p=0.001 for total symptoms). There was an improvement in both OSAS-specific (p<0.001) and general health-related quality of life, as reported by both caregivers (p=0.005) and the children themselves (p<0.001).

The percentage of children with scores in the clinically abnormal range decreased on PAP for all domains, with significant reductions seen in the percentage of children with pathological sleepiness on the Epworth scale, and with low quality of life (Table 3).
The effect of age, gender, race, BMI z-score, maternal education and baseline scores on neurobehavioral outcomes was assessed. Baseline scores had a significant effect for all outcomes (p=0.002 for OSA-18; p<0.0005 for all other outcomes). Other than baseline scores, the only other significant effect was for gender on the change in score of the Internalizing symptoms of the CBCL, with girls showing a greater improvement than boys (-6.9±6.9 vs -2.3±7.9 respectively, p=0.049).

To assess the relationship between the degree of adherence and behavioral outcomes, the correlation between adherence parameters and behavioral outcomes was measured. There was a significant correlation between the change in the Epworth score at 3 months and PAP adherence (mean minutes used/night: r = -0.411, p = 0.006; nights used: r = -0.348, p=0.028; Figure 4), but no significant correlation between other behavioral outcomes and PAP use.

Subjects With Developmental Delays

10 subjects had significant developmental delays. Exploratory analyses were performed for this small subset of children. There were similar findings to the total study group, with significant improvements in the Epworth scale (p=0.003), internalizing (p=0.024) and total behavior scores (p=0.049), and OSAS-specific (p=0.001) and general (p=0.037) quality of life.
Subjects Younger than Seven Years Of Age

As PAP is not approved by the Food and Drug Administration for children <7 years of age or weighing <40 lb (18 kg), this subgroup was evaluated separately in exploratory analyses. In this small subset (N=7; age 4.5 ± 1.7 years, range 2-6 years), significant improvements were found in sleepiness on the Epworth scale (p=0.012) and OSAS-specific quality of life (p=0.021).

DISCUSSION

PAP use is known to be highly effective at treating OSAS as demonstrated on polysomnography\textsuperscript{18}. However, the clinical benefits of using PAP in children have not been well-studied. It is very difficult to get young children to wear PAP\textsuperscript{18,21-23}. Furthermore, many children requiring PAP therapy have underlying chronic illnesses or developmental delays\textsuperscript{2,16-22}, further complicating efforts to improve adherence. It is therefore imperative to show that PAP use actually improves clinical outcomes in addition to improving polysomnographic abnormalities, before widespread pediatric PAP programs can be advocated. This study showed that PAP use was associated with significant changes in neurobehavioral parameters after only three months of use, even in a heterogeneous group of children with OSAS, including very young children and children with developmental delays. In addition to statistically significant improvements in neurobehavioral parameters, there was a reduction in the number of children falling in the clinically abnormal range (Table 3).
In adults, OSAS is associated with a wide range of neurocognitive deficits. These include deficits in daytime sleepiness, mood, cognitive processing, sustained attention, executive functioning, short term working memory and quality of life, all of which lead to diminished ability to execute various activities of daily living such as occupational performance, driving safety and psychosocial functioning\textsuperscript{24,25}. However, in adults PAP use has not been clearly shown to improve many of these deficits\textsuperscript{25,26}. A possible explanation for the improvement in function seen in children in the current study compared to the studies of adults may be that the children had a shorter duration of OSAS and therefore increased reversibility. Another explanation may be the increased plasticity of the child’s central nervous system. The improvements may have been due to both improvements in gas exchange during sleep and improvements in sleep fragmentation.

Although neurobehavioral consequences of OSAS have been investigated extensively in adults, the consequences in children have not been fully evaluated. There is emerging evidence that children with OSAS show deficits in neurocognitive performance, behavioral impairments and reduced school performance\textsuperscript{4,27-32}, similar to those noted in the current study. Several studies have shown that these neurocognitive/behavioral abnormalities are at least partially reversible with surgical treatment in otherwise healthy children\textsuperscript{27,30,33-35}, although these studies were limited by small sample sizes and/or lack of full polysomnography. Only a handful of studies have examined the impact of PAP therapy on daytime functioning in children with OSAS. A study of 13 obese adolescents with OSAS found improvements in school performance, vigilance and school-related quality of life in those who were adherent to PAP\textsuperscript{36}. Another study only evaluated
subjective measures, and found improvements in sleepiness but no change in subjective assessments of attention or behavior\textsuperscript{18}.

In this study, changes in behavioral function were seen after only 3 months of PAP use. The time required for maximal improvements in behavioral function is unknown but may well be longer than 3 months, and further studies with long-term follow-up are needed.

As might be expected, the use of PAP therapy with children can be challenging despite close follow up and support. In the current study, there was considerable variability in PAP adherence amongst subjects, with low overall adherence, consistent with findings from previous studies\textsuperscript{18,21,22,36}. Despite this, improvements were found in all neurobehavioral domains. Conceivably, better adherence would result in even further improvements. Surprisingly, however, a significant correlation between improvements and adherence was found only in regards to daytime sleepiness, as measured on the Epworth scale. Similarly, in adults, sleepiness improves in response to increased CPAP use\textsuperscript{37}. One reason for the lack of correlation between PAP use and other neurobehavioral outcomes in the current study may be the difference in physiologic sleep requirements over the age spectrum studied, and the differing degree of baseline neurobehavioral function in the subjects. Thus, the effects of wearing CPAP for 4 hours a night may be less beneficial in a two year old sleeping for 12 hours a night then in a 16 year old sleeping 8 hours a night.
In adults, 4 hours of PAP use per night is traditionally considered to be adequate adherence. The current study suggests that, in children, the longer the PAP is worn, the better the outcomes (at least in regards to daytime sleepiness). However, some benefit can be obtained from even small amounts of PAP use. Thus, any degree of PAP use should be encouraged.

In the current study, even children with significant developmental delays showed an improvement in some parameters with PAP. Therefore, PAP is recommended for this patient population, in order to optimize each child’s potential. Note that the study was underpowered for both the developmentally delayed subjects subset and the subset of children younger than 7 years of age, and may thus have missed other changes in behavioral parameters. Further studies of these high risk groups are warranted.

A limitation of this study is that a placebo group was not included, and reports from individuals other than the subjects (for some measures) and caregivers, such as teachers, were not obtained. Subjects and their caregivers were not blinded as to PAP treatment, and this may have impacted the responses to the surveys used as outcome measures.

The inclusion of children with a variety of underlying medical conditions and across the age spectrum was both a limitation and strength of this study. This is the first comprehensive study of the effects of PAP use in children, and thus the study was designed to include the typical pediatric patient populations requiring PAP therapy. The study results are therefore directly applicable to clinical pediatric sleep medicine practice. Further studies evaluating more homogeneous study groups are warranted in order to
more closely determine the relationship between PAP use and neurobehavioral outcomes.

In conclusion, the treatment of childhood OSAS with PAP therapy was associated with significant improvements in daytime sleepiness, symptoms of ADHD, internalizing behaviors and quality of life in children with OSAS, including young children and children with developmental delays. These improvements occurred despite a mean use of only three hours per night, suggesting that clinicians should encourage any PAP use, and not be discouraged when adherence is suboptimal. These findings have important implications in managing children with OSAS, as reinforcing PAP use will be beneficial in many domains of daily life.
FIGURE LEGENDS

Figure 1:

The box plots show the improvements in symptoms of attention deficit hyperactivity disorder as measured by the Conners scale (left panel) and CBCL Attention Scale (center panel), and changes in daytime sleepiness as measured by the Epworth Sleepiness Scale (right panel), before and after 3 months of positive airway pressure (PAP). There was a significant improvement in both symptoms of attention deficit hyperactivity disorder and sleepiness. The box represents the interquartile ranges which contains 50% of all values. The line across the box indicates the median. The whiskers extend from the box to the 90\textsuperscript{th} and 10\textsuperscript{th} percentiles, excluding outliers. Outliers (o) are defined as cases outside the 90\textsuperscript{th} and 10\textsuperscript{th} percentiles.

Figure 2:

The box plots show the changes in internalizing, externalizing and total scores on the Child Behavior Checklist (CBCL) before and after 3 months of positive airway pressure (PAP). There were significant improvements in internalizing and total behavior symptom scores, but not in externalizing symptoms. See legend of Figure 1 for description of the box plots.

Figure 3:

The box plots show the improvements in obstructive sleep apnea-specific (left panel, as measured by the OSA-18 scale) and general health related quality of life (center and right
panels, as measured by the caregiver and child PedsQL) before and after 3 months of positive airway pressure (PAP). See legend of Figure 1 for description of the box plots.

**Figure 4:**

The individual changes in Epworth Sleepiness Scale at 3 months, as a percentage of baseline, is shown on the y-axis, and positive airway pressure (PAP) adherence, reflected as mean minutes used/night, is shown on the x-axis. There was a significant correlation between PAP use and change in sleepiness.
ACKNOWLEDGMENTS

We thank all the children and families who participated in this study, and the sleep technologists for their dedication and professionalism.
Table 1: Study Group Characteristics

<p>| | |</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>N</strong></td>
<td>52</td>
</tr>
<tr>
<td><strong>Age (yr)</strong></td>
<td>12 ± 4</td>
</tr>
<tr>
<td><strong>Males</strong></td>
<td>36 (69)</td>
</tr>
<tr>
<td><strong>Race:</strong></td>
<td></td>
</tr>
<tr>
<td>African American</td>
<td>32 (62)</td>
</tr>
<tr>
<td>Caucasian</td>
<td>18 (35)</td>
</tr>
<tr>
<td>More than one race</td>
<td>2 (4)</td>
</tr>
<tr>
<td><strong>Hispanic ethnicity</strong></td>
<td>3 (6)</td>
</tr>
<tr>
<td><strong>BMI z-score</strong></td>
<td>2.0 ± 0.9</td>
</tr>
<tr>
<td><strong>Other diagnoses a:</strong></td>
<td></td>
</tr>
<tr>
<td>Obesity b</td>
<td>36 (69)</td>
</tr>
<tr>
<td>Genetic syndrome</td>
<td>9 (17)</td>
</tr>
<tr>
<td>Central nervous system abnormality</td>
<td>6 (11)</td>
</tr>
<tr>
<td>Craniofacial syndrome</td>
<td>3 (5)</td>
</tr>
<tr>
<td>Pulmonary disease</td>
<td>3 (5)</td>
</tr>
<tr>
<td>Growth hormone deficiency</td>
<td>1 (2)</td>
</tr>
<tr>
<td>Neurodevelopmental disability c</td>
<td>10 (19)</td>
</tr>
<tr>
<td><strong>Maternal education:</strong></td>
<td></td>
</tr>
<tr>
<td>Did not complete high school</td>
<td>2 (4)</td>
</tr>
<tr>
<td>Completed high school; no college</td>
<td>14 (27)</td>
</tr>
<tr>
<td>Some college</td>
<td>20 (39)</td>
</tr>
<tr>
<td>Completed college</td>
<td>9 (17)</td>
</tr>
<tr>
<td>-------------------</td>
<td>--------</td>
</tr>
<tr>
<td>Completed postgraduate degree</td>
<td>7 (14)</td>
</tr>
</tbody>
</table>

**PAP adherence:**

<table>
<thead>
<tr>
<th>Night used over 3 months</th>
<th>60 ± 25</th>
</tr>
</thead>
<tbody>
<tr>
<td>Average use per night (minutes)</td>
<td>170 ± 145</td>
</tr>
</tbody>
</table>

Data shown as mean ± SD or N (%). PAP, positive airway pressure

(a) Note that some children had multiple diagnoses.

(b) Obesity defined as body mass index ≥ 95th percentile for age and sex.\(^3^8\)

(c) Includes 6 children with Down syndrome, 1 with Prader-Willi syndrome, 1 with cerebral palsy, 1 with autism and 1 with a complex chromosomal disorder.
Table 2: Polysomnographic Data (N=51)

<table>
<thead>
<tr>
<th></th>
<th>Baseline</th>
<th>On PAP</th>
<th>P value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sleep efficiency (% total sleep time)</td>
<td>82 ± 11</td>
<td>83 ± 18</td>
<td>0.81</td>
</tr>
<tr>
<td>Arousal index (N/hr)</td>
<td>23 ± 15</td>
<td>16 ± 18</td>
<td>0.019</td>
</tr>
<tr>
<td>Stage N1 (%TST)</td>
<td>8.8 ± 5.9</td>
<td>6.1 ± 6.7</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Stage N2 (%TST)</td>
<td>49.1 ± 9.9</td>
<td>46.7 ± 11.2</td>
<td>0.16</td>
</tr>
<tr>
<td>Stage N3 (%TST)</td>
<td>22.3 ± 8.8</td>
<td>24.6 ± 13.5</td>
<td>0.18</td>
</tr>
<tr>
<td>Rapid eye movement sleep (% TST)</td>
<td>19.7 ± 6.9</td>
<td>22.5 ± 7.5</td>
<td>0.036</td>
</tr>
<tr>
<td>Apnea hypopnea index (N/hr)</td>
<td>18.1 ± 14.7</td>
<td>2.0 ± 2.3</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>SpO₂ nadir (%)</td>
<td>80 ± 13</td>
<td>90 ± 4</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Time with SpO₂ &lt; 90% (% total sleep time)</td>
<td>4.9 ± 9.1</td>
<td>0.1 ± 0.5</td>
<td>0.001</td>
</tr>
<tr>
<td>Peak end-tidal CO₂ (mm Hg)</td>
<td>57 ± 5</td>
<td>55 ± 5</td>
<td>0.027</td>
</tr>
<tr>
<td>Time with end-tidal PCO₂ &gt; 50 mm Hg (% total sleep time)</td>
<td>16.7 ± 22.4</td>
<td>12.0 ± 19.6</td>
<td>0.42</td>
</tr>
</tbody>
</table>

Data shown as mean ± SD. PAP, positive airway pressure; TST, total sleep time.
Table 3: Frequency of Children Falling in the Clinically Abnormal Range on Neurobehavioral Measures at Baseline and Following PAP Therapy

<table>
<thead>
<tr>
<th>Measure</th>
<th>Baseline</th>
<th>On PAP</th>
<th>P value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Conners Abbreviated Symptom Questionnaire a</td>
<td>10 (19.2)</td>
<td>6 (11.5)</td>
<td>0.289</td>
</tr>
<tr>
<td>Modified Epworth Sleepiness Scale</td>
<td>14 (26.9)</td>
<td>5 (9.6)</td>
<td>0.004</td>
</tr>
<tr>
<td>Child Behavior Checklist</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Attention problems</td>
<td>13 (25.0)</td>
<td>8 (15.4)</td>
<td>0.18</td>
</tr>
<tr>
<td>Internalizing</td>
<td>13 (25.0)</td>
<td>9 (17.3)</td>
<td>0.34</td>
</tr>
<tr>
<td>Externalizing</td>
<td>8 (15.4)</td>
<td>6 (11.5)</td>
<td>0.73</td>
</tr>
<tr>
<td>Total</td>
<td>17 (32.7)</td>
<td>12 (23.1)</td>
<td>0.063</td>
</tr>
<tr>
<td>OSAS-18</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Moderate impairment</td>
<td>28 (53.8)</td>
<td>5 (9.6)</td>
<td>&lt; 0.001</td>
</tr>
<tr>
<td>Large impairment</td>
<td>9 (17.3)</td>
<td>2 (3.8)</td>
<td>0.039</td>
</tr>
<tr>
<td>PedsQL</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Impairment (caregiver report)</td>
<td>27 (51.9)</td>
<td>16 (30.8)</td>
<td>0.013</td>
</tr>
<tr>
<td>Impairment (child report) b</td>
<td>26 (61.9)</td>
<td>13 (31.0)</td>
<td>0.002</td>
</tr>
</tbody>
</table>

Data shown as N (%). P values based on McNemar tests of equality of paired proportions. PAP, positive airway pressure

(a) N=51

(b) N = 42
Reference List


Ref Type: Abstract


Figure 1:

- Conners Scale: Pre PAP and Post PAP, showing a significant decrease with $P < 0.001$.
- CBCL Attention Scale: Pre PAP and Post PAP, showing a significant decrease with $P = 0.005$.
- Epworth Sleepiness Scale: Pre PAP and Post PAP, showing a significant decrease with $P < 0.001$. 
Figure 2:
Figure 3:

- OSA-18: Pre PAP vs Post PAP, $P < 0.001$
- Caregiver PedsQL: Pre PAP vs Post PAP, $P = 0.005$
- Child PedsQL: Pre PAP vs Post PAP, $P < 0.001$
Figure 4:

Change in Epworth Sleepiness Scale (%) vs. PAP use (average minutes/night).

$r = -0.411$, $p = 0.006$.
ONLINE SUPPLEMENT

METHODS

This study was conducted prospectively as part of a clinical trial comparing two modes of PAP delivery: CPAP vs bilevel pressure release (Bi-Flex); no difference in adherence or efficacy was found between the modes\textsuperscript{6}. The study was registered at Clinicaltrials.gov (#NCT00458406).

Children with OSAS aged 2-16 years, who were naïve to PAP and clinically required PAP, were eligible. The study was approved by the Institutional Review Board of The Children’s Hospital of Philadelphia. Written informed consent was obtained from the parent/legal guardian, and assent from children 7 years of age or older when able.

All subjects underwent baseline clinical polysomnography prior to study entry. Subjects then had a 2-week habituation period at home, followed by a PAP titration study. Adherence was optimized by providing free equipment, frequent phone calls and visits to address any problems, as well as behavioral modification to facilitate PAP adaption\textsuperscript{7}. At the end of 3 months, polysomnography was repeated on PAP to evaluate efficacy, and objective adherence data were downloaded (EncorePro2, Philips Respironics, Murraysville, PA).

Neurobehavioral surveys were administered at baseline and after 3 months of PAP use. Based on known data regarding the domains affected by childhood OSAS, the following were evaluated:

1. **Sleepiness**, using the *Epworth Sleepiness Scale* modified for children\textsuperscript{8}. This is a proxy measure of daytime sleepiness modified for use in children aged 2-16, and used in studies of
children with and without neurologic disorders\textsuperscript{8,9,10}. A score > 12 was considered abnormal as it was >95\textsuperscript{th} percentile for normal children\textsuperscript{8}.

2. Behavioral problems, using the Child Behavior Checklist (CBCL)\textsuperscript{11,12}. This is a survey of behavior competencies that yields standardized, age-adjusted scores on internalizing, externalizing and total behavior difficulties. Scores between 60-63 are borderline; scores > 63 are abnormal.

3. ADHD, using both the Conners Abbreviated Symptom Questionnaire and the Attention Problems subscale of the CBCL. The Conners scale evaluates inattention, distractibility, and overactivity. Scores range from 0-30; ≥ 15 is considered clinically relevant\textsuperscript{13}.

4. Quality of life was measured using two instruments. The Pediatric Quality of Life Inventory (PedsQL)\textsuperscript{14} is a well-validated measure of global quality of life. The score ranges from 0-100; the cutoff for moderate to severe impairment in quality of life is >73 for children <8 years, and ≥65 for children ≥8 years\textsuperscript{15}. The OSAS-18\textsuperscript{16} is a composite of OSAS-related symptoms and disease-specific quality of life. Scores range from 18-126. Scores <60 suggest a small impact, 60-80 suggest a moderate impact and >80 suggest a large impact of OSAS on quality of life.

Surveys were completed by the same caregiver at each time point. In addition, developmentally able youths aged 11-18 completed the CBCL Youth Self Report, and those ≥5 years completed the PedsQL.

**Statistical Analysis**

Unless otherwise specified, data are shown as mean ± SD. Kolmogorov-Smirnov tests were used to examine normalcy of distribution. Differences between subjects at baseline vs 3 months were
analyzed using paired Student’s t-tests, Wilcoxon signed rank tests or McNemar tests of equality of paired proportions. Differences between those who dropped out vs those who completed the study were evaluated using unpaired Student’s t-tests, Mann Whitney rank sum tests or Fisher exact test. Pearson or Spearman correlations were used to determine the relationship between adherence and behavioral outcomes. p<0.05 was considered significant.

In order to explore potential effects of various demographic variables on neurobehavioral outcomes, analysis of covariance (ANCOVA) models were examined, followed by post-hoc pairwise tests, using the Bonferroni method to correct for multiple comparisons. For each of the neurobehavioral outcomes separately, two series of models were developed; in the first series, the final score was used as the outcome and the baseline score was used as an additional covariate, and in the second series, the difference score (final minus baseline) was the outcome. For both series, the factors included gender and race (African American vs other) and the covariates included age, BMI z-score, maternal education, and, in the first series of models, the baseline score.